相关实验视频
Updated: Jul 7, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.7K
双重抗血栓治疗剂量取决于改变静血栓的结构和功能
Christopher D Mansi1, Jenna R Severa1, Joseph N Wilhelm1
1Department of Medicine, Cardeza Center for Hemostasis, Thrombosis, and Vascular Biology, Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Journal of thrombosis and haemostasis : JTH
|December 24, 2023
概括
双重抗血栓治疗与抗血小板和抗凝剂药物增加出血风险. 结合这些药物会比单独使用任何药物更严重地损害血静,这突显了双重抗血栓治疗的风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 血栓形成研究研究
背景情况:
- 抗血栓药物,包括抗凝固剂和抗血小板药物,携带出血风险.
- 结合这些药物类别可以加剧出血.
- 以前的研究表明,抗血小板药与抗凝血药在体内对静血栓形成的明显影响.
研究的目的:
- 调查双重抗血栓治疗 (联合抗血小板和抗凝剂) 与单一治疗相比,是否会改变静血栓结构和功能.
- 评估P2Y12抗剂和XA因子抑制剂联合对血液静止的影响.
主要方法:
- 小鼠接受了单独或组合使用克洛皮多格雷尔 (P2Y12抗剂) 和里瓦洛克萨班 (XA因子抑制剂) 的治疗,剂量不同.
- 血液静止反应使用小鼠 jugular 静脉穿孔模型进行评估.
- 使用多光子光显微镜量化了血小板积累,纤维素沉积和出血时间.
主要成果:
- 单独使用克洛皮多格雷尔可减少血小板的积累,仅在高剂量时才会延长出血.
- 利瓦洛克萨班单独降低了纤维素沉积,没有出血的影响.
- 双重治疗显示了与单一治疗相似的血小板/纤维素水平,但在隔离时安全的剂量下降了血静.
结论:
- 与单一治疗相比,联合抗血小板和抗凝药疗法会加剧出血风险.
- 这种效应可能源于ADP和血小板激活的联合抑制.
- 这些发现有助于更好地了解与双重抗血栓策略相关的出血风险.
相关概念视频
Formation of the Platelet Plug
6.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
706
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
706
Clot Retraction and Fibrinolysis
6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Introduction to Hemostasis
7.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.9K

